Direct binding of ledipasvir to HCV NS5A: mechanism of resistance to an HCV antiviral agent.
about
KASL clinical practice guidelines: management of hepatitis CVirologic Tools for HCV Drug Resistance TestingCritical role of Casein kinase 2 in hepatitis C NS5A-mediated inhibition of Kv2.1 K(+) channel function.Successful Retreatment of Chronic HCV Genotype-1 Infection With Ledipasvir and Sofosbuvir After Initial Short Course Therapy With Direct-Acting Antiviral Regimens.In Vitro Antiviral Activity and Resistance Profile Characterization of the Hepatitis C Virus NS5A Inhibitor LedipasvirSynergistic Activity of Combined NS5A Inhibitors.An insight into the molecular characteristics of hepatitis C virus for clinicians.Resistance Mechanisms in Hepatitis C Virus: implications for Direct-Acting Antiviral Use.The hepatitis C viral nonstructural protein 5A stabilizes growth-regulatory human transcripts.Advanced Prodrug Strategies in Nucleoside and Non-Nucleoside Antiviral Agents: A Review of the Recent Five Years.Characterization of the anti-hepatitis C virus activity of new non-peptidic small-molecule cyclophilin inhibitors with a potential for broad anti-Flaviviridae activity.Grazoprevir/elbasvir treatment for the relapse of HCV genotype 1b infection after ledipasvir/sofosbuvir: A case reportHepatitis C resistance to NS5A inhibitors: Is it going to be a problem?
P2860
Q26752471-3D633CC1-8B93-4695-9CAF-73E47425F26DQ26774374-EAE30856-AE23-4DCC-95B0-D7FAFC98CD3FQ36373257-FBBCFB25-027E-461B-9932-484B865ABAF2Q36446122-B8132BCC-5D3A-423D-AA92-75E007195D14Q38740523-1FF99E6D-F35E-4C97-8FCB-6BE3BECE69C1Q38741143-F7B2FAAB-A2DB-49C3-B2D3-D84FF70345D4Q38825949-FD01E471-789B-404D-98D8-763B3A2F6BF9Q39301797-14A5E032-C8A6-454D-B7AF-933BD833DC6AQ47547598-D979A9C1-09F4-4E62-8631-72DA8DB34785Q47611417-DCF3546A-3D4C-4E1D-A3F6-2BD8ADFC560DQ54212189-D262193D-8EFA-4247-BAFE-346A0FC9D90FQ56524474-381354D1-8C93-437B-B0C8-D52048657462Q57491238-00C67FE1-4DA2-4D6B-B9FB-0394244C39B3
P2860
Direct binding of ledipasvir to HCV NS5A: mechanism of resistance to an HCV antiviral agent.
description
2015 nî lūn-bûn
@nan
2015年の論文
@ja
2015年論文
@yue
2015年論文
@zh-hant
2015年論文
@zh-hk
2015年論文
@zh-mo
2015年論文
@zh-tw
2015年论文
@wuu
2015年论文
@zh
2015年论文
@zh-cn
name
Direct binding of ledipasvir t ...... nce to an HCV antiviral agent.
@ast
Direct binding of ledipasvir t ...... nce to an HCV antiviral agent.
@en
type
label
Direct binding of ledipasvir t ...... nce to an HCV antiviral agent.
@ast
Direct binding of ledipasvir t ...... nce to an HCV antiviral agent.
@en
prefLabel
Direct binding of ledipasvir t ...... nce to an HCV antiviral agent.
@ast
Direct binding of ledipasvir t ...... nce to an HCV antiviral agent.
@en
P2093
P2860
P1433
P1476
Direct binding of ledipasvir t ...... nce to an HCV antiviral agent.
@en
P2093
Anita Niedziela-Majka
Darryl Kato
Guofeng Cheng
Hyock Joo Kwon
John O Link
Katherine M Brendza
Katie Chan
Roman Sakowicz
Thorsten Kirschberg
Weimei Xing
P2860
P304
P356
10.1371/JOURNAL.PONE.0122844
P407
P577
2015-04-09T00:00:00Z